Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

被引：3
作者：
Hoyle, Christopher [1 ]
Dyer, Matthew [1 ]
机构：
[1] AstraZeneca, Acad House,136 Hills Rd, Cambridge CB2 8PA, Cambs, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 05期
关键词：
D O I：
10.1016/j.jtho.2018.02.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
[41]   Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer [J].
Aguilar-Serra, J. ;
Gimeno-Ballester, V ;
Pastor-Clerigues, A. ;
Milara, J. ;
Trigo-Vicente, C. ;
Cortijo, J. .
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) :637-646
[42]   Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer [J].
Kim, Young Hak ;
Mishima, Michiaki .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) :E81-E82
[43]   COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB PLUS BEVACIZUMAB AS FIRST-LINE THERAPY FOR ADVANCED EGFR MUTATION-POSITIVE NON-SQUAMOUS NONSMALL CELL LUNG CANCER IN JAPAN [J].
Yoshioka, S. ;
Chen, W. ;
Maeda, T. ;
Morimoto, K. ;
Moriwaki, K. ;
Shimozuma, K. .
VALUE IN HEALTH, 2023, 26 (06) :S129-S129
[44]   Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer [J].
Su, Po-Lan ;
Wu, Yi-Lin ;
Chang, Wei-Yuan ;
Ho, Chung-Liang ;
Tseng, Yau-Lin ;
Lai, Wu-Wei ;
Su, Wu-Chou ;
Lin, Chien-Chung ;
Yang, Szu-Chun .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
[45]   Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer [J].
Su, P-L. ;
Wu, Y-L. ;
Chang, W-Y. ;
Su, W-C. ;
Yang, S-C. ;
Lin, C-C. .
ANNALS OF ONCOLOGY, 2018, 29
[46]   PREVENTING AND TREATING BRAIN METASTASES WITH THREE FIRST-LINE EGFR-TYROSINE KINASE INHIBITORS IN PATIENTS WITH EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER [J].
Su, Po-Lan ;
Wu, Yi-Lin ;
Chang, Wei-Yuan ;
Lin, Chien-Chung ;
Yang, Szu-Chun .
RESPIROLOGY, 2018, 23 :285-285
[47]   Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US [J].
Gautam, S. ;
Herms, L. ;
Bartolome, L. ;
Pastel, M. ;
Wilner, K. ;
Fisher, M. ;
Ivanova, J. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S618-S619
[48]   Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer [J].
Aguiar, Pedro N., Jr. ;
Haaland, Benjamin ;
Park, Wungki ;
Tan, Pui San ;
del Giglio, Auro ;
Lopes, Gilberto de Lima, Jr. .
JAMA ONCOLOGY, 2018, 4 (08) :1080-1084
[49]   Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer [J].
Meinrenken, Susanne .
PNEUMOLOGIE, 2018, 72 (04) :246-246
[50]   First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting [J].
Park, Keunchil ;
Lim, Darren Wan-Teck ;
Okamoto, Isamu ;
Yang, James Chih-Hsin .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
12345